Thalidomide

Drug

Related News

BMS CELMoD Mezigdomide Doubles PFS in Myeloma as FDA Reviews Iberdomide

May 29, 2026

BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.

GLP-1 Drugs Discovered in Fish Research Now Treat Multiple Conditions

Apr 07, 2026

GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.